Welcome to our dedicated page for Lineage Cell Therapeutics news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell Therapeutics stock.
Lineage Cell Therapeutics, Inc. (Symbol: LCTX) is a clinical-stage biotechnology company that is pioneering the development and commercialization of novel therapies designed to address degenerative diseases. With a foundation built on pluripotent cell technology, Lineage Cell's innovative approach leverages cells capable of transforming into any type of cell in the human body. This groundbreaking capability allows for therapies aimed at regenerating or replacing damaged cells and tissues, providing hope for conditions that currently have no cure.
The company's pipeline is robust and diverse, encompassing several key product candidates:
- OpRegen: A retinal pigment epithelium transplant therapy targeting dry age-related macular degeneration, a leading cause of vision loss among the elderly.
- OPC1: An oligodendrocyte progenitor cell therapy designed to treat acute spinal cord injuries by promoting cell replacement and recovery.
- VAC2: An allogeneic cancer immunotherapy utilizing antigen-presenting dendritic cells to fight non-small cell lung cancer.
- ANP1: A promising therapy involving the transplant of allogeneic auditory neuron progenitor cells to combat hearing loss.
- PNC1: An innovative approach using allogeneic photoreceptor cell transplants aimed at treating vision loss.
Lineage Cell Therapeutics is committed to addressing large unmet medical needs through its cutting-edge technologies. The company's clinical-stage programs are supported by a premier collection of pluripotent cell assets, positioning it at the forefront of regenerative medicine.
Recent achievements include significant progress in clinical trials, strategic partnerships, and advancements in their product development pipeline. Financially, the company remains poised for growth with a clear focus on expanding its therapeutic offerings and enhancing shareholder value.
Stay informed with the latest updates and developments at Lineage Cell Therapeutics as they continue to advance their mission of transforming the treatment landscape for degenerative diseases.
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. announces the presentation of 24-month results from a Phase 1/2a clinical study of OpRegen for geographic atrophy in AMD patients at the 2024 Retinal Cell & Gene Therapy Innovation Summit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
-
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. (LCTX) announced preclinical results of RG6501 (OpRegen) study to be presented at the 2024 ARVO Annual Meeting. The study evaluates survival and distribution in retinal pigmented epithelium (RPE) of mini-pigs post-administration via subretinal delivery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
-
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. reported positive financial results for Q4 and full year 2023, highlighting key developments in their collaboration with Roche and Genentech for OpRegen in AMD patients, IND clearance for OPC1, and initiation of a new clinical trial. The company also strengthened its balance sheet through a $14 million offering. Financially, Lineage saw a slight increase in revenues and a decrease in operating expenses for Q4, with a net loss of $4.8 million. For the full year, revenues decreased, but operating expenses also decreased, resulting in a net loss of $21.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.04%
Tags
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. (LCTX) will report its Q4 and full year 2023 financial results on March 7, 2024. A conference call and webcast will follow to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. receives FDA clearance for Investigational New Drug amendment for OPC1, an investigational allogeneic oligodendrocyte progenitor cell transplant for spinal cord injury. The company plans to conduct the DOSED clinical study to evaluate a novel delivery device in subacute and chronic SCI patients, with the first clinical site expected to open in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
-
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. (LCTX) closes a registered direct offering, selling 13,461,540 common shares at $1.04 per share, raising $14.0 million. Broadwood Partners and Don M. Bailey, board members, participated. The offering aims to bolster the balance sheet for upcoming milestones without dilutive elements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. (LCTX) has announced a registered direct offering of 13,461,540 common shares at an offering price of $1.04 per share. The agreement with investors was entered into before the markets opened on February 6, 2024. The closing of the offering is expected soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.73%
Tags
-
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. (LCTX) announced positive results from a Phase 1/2a clinical study for OpRegen in treating geographic atrophy (GA) secondary to advanced age-related macular degeneration (AMD). The study showed retinal structure improvements, with the data set to be presented at the 2024 Angiogenesis, Exudation, and Degeneration Meeting. The virtual meeting, sponsored by the University of Miami Health System Bascom Palmer Eye Institute, will feature the presentation by Allen Ho, MD, FACS, FASRS, on behalf of Roche and Genentech.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
-
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. (LCTX) submits an Investigational New Drug amendment (INDa) to the U.S. FDA for OPC1, its allogeneic oligodendrocyte progenitor cell transplant, for spinal cord injury treatment. The company plans to initiate the DOSED clinical study to evaluate the safety and utility of a novel spinal cord delivery device. OPC1 aims to improve the quality of life and restore functional activity in traumatic cervical or thoracic SCI patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.48%
Tags
News
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. (LCTX) reported financial and operating results, including updates on the Phase 2a clinical study of RG6501 (OpRegen®) in patients with Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD) under management of Genentech, a Member of the Roche Group. The company also presented additional OpRegen data at the 23rd Annual EURETINA Congress and 2023 Eyecelerator Meetings. Key highlights include rapid improvement in outer retinal structure in patients, U.S. Patent issuance for manufacturing and differentiation process for retinal pigment epithelial (RPE) cells, and ongoing development activities for OPC1 and a hypoimmune pluripotent cell line for neurology indications in partnership with Eterna Therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
FAQ
What is the current stock price of Lineage Cell Therapeutics (LCTX)?
The current stock price of Lineage Cell Therapeutics (LCTX) is $0.558 as of December 20, 2024.
What is the market cap of Lineage Cell Therapeutics (LCTX)?
The market cap of Lineage Cell Therapeutics (LCTX) is approximately 118.5M.
What does Lineage Cell Therapeutics, Inc. specialize in?
Lineage Cell Therapeutics specializes in developing and commercializing novel cell therapies for treating degenerative diseases.
What are the main product candidates of Lineage Cell Therapeutics?
The main product candidates include OpRegen, OPC1, VAC2, ANP1, and PNC1.
What is OpRegen?
OpRegen is a retinal pigment epithelium transplant therapy aimed at treating dry age-related macular degeneration.
How does Lineage Cell Therapeutics utilize pluripotent cells?
Lineage Cell Therapeutics uses pluripotent cells capable of becoming any cell type to regenerate or replace affected cells and tissues.
What is OPC1 designed to treat?
OPC1 is an oligodendrocyte progenitor cell therapy for treating acute spinal cord injuries.
What type of cancer is VAC2 targeting?
VAC2 targets non-small cell lung cancer using allogeneic cancer immunotherapy.
What recent achievements has Lineage Cell Therapeutics made?
Recent achievements include progress in clinical trials, strategic partnerships, and advancements in their product development pipeline.
What is ANP1?
ANP1 is a therapy involving the transplant of allogeneic auditory neuron progenitor cells to treat hearing loss.
What is the financial outlook of Lineage Cell Therapeutics?
Lineage Cell Therapeutics is focused on growth, expanding its therapeutic offerings, and enhancing shareholder value.
Where can I find the latest updates on Lineage Cell Therapeutics?
The latest updates and developments can be found on their website and through financial news platforms.
Lineage Cell Therapeutics, Inc.
NYSE:LCTX
LCTX Rankings
LCTX Stock Data
118.47M
219.17M
0.44%
50.56%
8.44%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States of America
CARLSBAD